Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 5 | 5 |
| List of Tables | 7 | 1 |
| List of Figures | 8 | 2 |
| Emerging Pharmaceutical Market: Brazil - Introduction | 10 | 1 |
| Emerging Pharmaceutical Market: Brazil - Industry Characterstics | 11 | 20 |
| Market Size and Market Forecast | 11 | 1 |
| Market Share by Therapy Area | 12 | 1 |
| Branded versus Generic Market Share | 13 | 1 |
| R&D Expenditure Innovations | 14 | 1 |
| Increased Screening Rates during R&D | 14 | 1 |
| Top Pharmaceutical Companies in Brazil | 15 | 1 |
| Domestic Players | 15 | 1 |
| EMS | 15 | 1 |
| Ach | 16 | 1 |
| Eurofarma | 17 | 1 |
| Medley | 18 | 1 |
| Hypermarcas | 19 | 1 |
| Foreign Players | 20 | 1 |
| Sanofi | 20 | 1 |
| Novartis | 21 | 1 |
| Pfizer | 22 | 1 |
| Roche | 23 | 1 |
| Drivers and Challenges | 24 | 1 |
| Drivers | 24 | 1 |
| Demographics and Increasing Disposable Income | 24 | 1 |
| Increasing Prevalence of Lifestyle Diseases | 24 | 1 |
| Innovations in R&D | 24 | 1 |
| Efficient Distribution Network | 24 | 1 |
| Barriers | 25 | 1 |
| Regional Inequalities | 25 | 1 |
| Patent Expiries and Less Differentiated Products to Fill the Productivity Gap | 25 | 1 |
| Fast Growth of Local Players | 25 | 1 |
| Regulatory and Legal Framework | 25 | 1 |
| Healthcare Delivery System | 26 | 1 |
| Brazil Healthcare Delivery Opportunities | 26 | 1 |
| An Attractive Emerging Pharmaceutical Market | 26 | 1 |
| Home Healthcare Delivery Market | 27 | 1 |
| Government - The Largest Buyer of Pharmaceutical Products and Services | 27 | 1 |
| Investment Opportunities in Hospital Information Systems Sector | 27 | 1 |
| Telemedicine | 27 | 1 |
| Brazil Healthcare Delivery Challenges | 28 | 1 |
| High Taxes | 28 | 1 |
| Weak Intellectual Property Protection | 28 | 1 |
| Fast growth of local players- generics and branded-generics | 28 | 1 |
| Pending Regulatory Approvals | 28 | 1 |
| PESTLE Analysis | 29 | 1 |
| Political factors | 29 | 1 |
| Economic factors | 29 | 1 |
| Social factors | 29 | 1 |
| Technological factors | 30 | 1 |
| Legal factors | 30 | 1 |
| Environmental factors | 30 | 1 |
| Emerging Pharmaceutical Market: Brazil - Macroeconomic Environment | 31 | 16 |
| Demographic Analysis | 31 | 1 |
| Population Size, Growth, and Structure | 31 | 3 |
| Disease Overview in Brazil | 34 | 1 |
| Number of Deaths Occurring due to Major Diseases in Brazil | 34 | 1 |
| HIV/AIDS | 35 | 1 |
| Cardiovascular Diseases (CVD) | 36 | 1 |
| Diabetes | 37 | 1 |
| Cancer | 38 | 1 |
| GDP | 39 | 2 |
| Per Capita Income | 41 | 1 |
| Context | 41 | 1 |
| Analytical Framework | 41 | 1 |
| Healthcare Expenditure | 42 | 1 |
| Context | 42 | 1 |
| Analytical Framework | 43 | 1 |
| Healthcare Infrastructure | 44 | 1 |
| Analytical Framework | 45 | 2 |
| Emerging Pharmaceutical Market: Brazil -Healthcare Regulation | 47 | 11 |
| Pharmaceutical Regulation in Brazil | 47 | 1 |
| Drug Approval Process | 47 | 1 |
| Drug Registration Process | 48 | 1 |
| Patents and Generics (IPR) | 49 | 1 |
| Health Insurance Coverage | 50 | 1 |
| Clinical Trials | 50 | 1 |
| Context | 50 | 1 |
| Analytical Framework | 51 | 1 |
| Pricing and Reimbursement | 51 | 1 |
| Private Insurance | 52 | 3 |
| Hospotels | 55 | 1 |
| Cosmetic Travel | 55 | 1 |
| Regulatory Bodies | 56 | 1 |
| Ministry of Health (MOH) | 56 | 1 |
| Ag ncia Nacional de Vigil ncia Sanit ria (ANVISA) | 56 | 1 |
| National Private Healthcare Insurance Agency (ANS) | 57 | 1 |
| Unified Health System (UHS also called as SUS in Brazil) | 57 | 1 |
| Emerging Pharmaceutical Market: Brazil - Industry Trends | 58 | 9 |
| Mergers and Acquisitions | 58 | 1 |
| M&A Deals by Year | 58 | 1 |
| Deal by Value | 59 | 1 |
| Recent M&A Deals | 60 | 1 |
| Top Five M&As | 60 | 1 |
| Amgen acquires Bergamo | 60 | 1 |
| Pearle Europe Acquires Fotoptica and Fabrica de Oculos | 60 | 1 |
| Sanofi Acquires Medley Pharmaceuticals | 60 | 1 |
| Pfizer Acquires a 40% Stake in Laboratorio Teuto Brasileiro | 60 | 1 |
| Aspen Pharmacare Acquires Cellofarm from Strides Latina | 60 | 1 |
| Co-development Deals | 61 | 1 |
| Deals by Year | 61 | 1 |
| Deal by Value | 62 | 1 |
| Recent Co-development Deals | 62 | 1 |
| Top Co-development Deals | 63 | 1 |
| KYORIN Pharma Enters into an Agreement with Diachi Sankyo Brasil | 63 | 1 |
| GlaxoSmithKline and Oswaldo Cruz Foundation - 2009 | 63 | 1 |
| GlaxoSmithKline Enters into Co-Development Agreement with Oswaldo Cruz Foundation - 2010 | 63 | 1 |
| Cryo-Cell International Enters into Research and Development Agreement with Cryopraxis Cryobiology | 63 | 1 |
| Licensing Agreements | 64 | 1 |
| Deals by Year | 64 | 1 |
| Deals by Value | 65 | 1 |
| Recent Licensing Agreements | 65 | 1 |
| Top Licensing Agreements | 66 | 1 |
| Cell Point Enters into Licensing Agreement with MJM Productos Farmaceuticos | 66 | 1 |
| Oxford Nutrascience Enters into Licensing Agreement with Ache Laboratories | 66 | 1 |
| iBio Enters into Licensing Agreement with Bio-Manguinhos | 66 | 1 |
| Emerging Pharmaceutical Market: Brazil - CRO Industry | 67 | 13 |
| Contract Research Organization (CRO) Market Size and Growth | 67 | 1 |
| PPD | 67 | 1 |
| Business Description | 68 | 1 |
| PRA International | 69 | 1 |
| Business Description | 69 | 1 |
| ICON | 70 | 1 |
| Business Description | 70 | 1 |
| Theorem Clinical Research | 71 | 1 |
| Business Description | 71 | 1 |
| PAREXEL | 72 | 1 |
| Business Description | 72 | 1 |
| Intrials | 73 | 1 |
| Business Description | 73 | 1 |
| Eurotrials | 74 | 1 |
| Business Description | 74 | 1 |
| PGS Medical/Statistics | 75 | 1 |
| Business Description | 75 | 1 |
| INC Research | 76 | 1 |
| Business Description | 76 | 1 |
| Chiltern | 77 | 1 |
| Business Description | 77 | 1 |
| Covance | 78 | 1 |
| Business Desription | 78 | 1 |
| Quintiles | 79 | 1 |
| Business Description | 79 | 1 |
| Emerging Pharmaceutical Market: Brazil - Appendix | 80 | 3 |
| Market Definitions | 80 | 1 |
| Abbreviations | 80 | 1 |
| Sources | 80 | 1 |
| Research Methodology | 81 | 2 |
| Industry Performance | 81 | 1 |
| Macroeconomic Environment | 81 | 1 |
| Healthcare Regulations | 82 | 1 |
| Industry Trends | 82 | 1 |
| Contact Us | 82 | 1 |
| Disclaimer | 82 | 1 |